Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Print PDF (285K) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Nishikawa, F.
Right arrow Articles by Nishikawa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nishikawa, F.
Right arrow Articles by Nishikawa, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2003, Vol. 31, No. 7 1935-1943
© 2003 Oxford University Press

Inhibition of HCV NS3 protease by RNA aptamers in cells

Fumiko Nishikawa, Nobuko Kakiuchi, Kohei Funaji1, Kotaro Fukuda, Satoru Sekiya and Satoshi Nishikawa

Institute for Biological Resources and Functions, National Institute of Advanced Industrial Sciences and Technology (AIST), 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan and 1 Mitsubishi Gas Chemical Company, Inc., Marunouchi, Tokyo 100-8324, Japan

Nobuko Kakiuchi, Faculty of Pharmaceutical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-0934, Japan

Non-structural protein 3 (NS3) of hepatitis C virus (HCV) has two distinct activities, protease and helicase, which are essential for HCV proliferation. In previous work, we obtained RNA aptamers (G9-I, II and III) which specifically bound the NS3 protease domain ({Delta}NS3), efficiently inhibiting protease activity in vitro. To utilize these aptamers in vivo, we constructed a G9 aptamer expression system in cultured cells, using the cytomegarovirus enhancer + chicken ß-actin globin (CAG) promoter. By conjugating the cis-acting genomic human hepatitis delta virus (HDV) ribozyme and G9-II aptamer, a chimeric HDV ribozyme-G9-II aptamer (HA) was constructed, which was used to produce stable RNA in vivo and to create tandem repeats of the functional unit. To target the transcribed RNA aptamers to the cytoplasm, the minimal mutant of constitutive transport element (CTE), derived from type D retroviruses, was conjugated at the 3' end of HA (HAC). Transcript RNAs from (HA)n and (HAC)n were processed into the G9-II aptamer unit by the cis-acting HDV ribozyme, both in vitro and in vivo. Efficient protease inhibition activity of HDV ribozyme-G9-II aptamer expression plasmid was demonstrated in HeLa cells. Protease inhibition activity level of tandem chimeric aptamers, (HA)n and (HAC)n, rose with the increase of n from 1 to 4.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 FASEB J.Home page
Y.-C. Chang, W.-C. Kao, W.-Y. Wang, W.-Y. Wang, R.-B. Yang, and K. Peck
Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses
FASEB J, September 1, 2009; 23(9): 3078 - 3088.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. L. Johnson, D. M. Owen, and M. Gale Jr.
Functional and Therapeutic Analysis of Hepatitis C Virus NS3{middle dot}4A Protease Control of Antiviral Immune Defense
J. Biol. Chem., April 6, 2007; 282(14): 10792 - 10803.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
W. James
Aptamers in the virologists' toolkit
J. Gen. Virol., February 1, 2007; 88(2): 351 - 364.
[Abstract] [Full Text] [PDF]

Home page
 RNAHome page
M. Ellingham, D. H.J. Bunka, D. J. Rowlands, and N. J. Stonehouse
Selection and characterization of RNA aptamers to the RNA-dependent RNA polymerase from foot-and-mouth disease virus
RNA, November 1, 2006; 12(11): 1970 - 1979.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
T. Umehara, K. Fukuda, F. Nishikawa, M. Kohara, T. Hasegawa, and S. Nishikawa
Rational Design of Dual-Functional Aptamers That Inhibit the Protease and Helicase Activities of HCV NS3
J. Biochem., March 1, 2005; 137(3): 339 - 347.
[Abstract] [Full Text] [PDF]

Home page
 RNAHome page
B. HWANG, J. S. CHO, H. J. YEO, J.-H. KIM, K. M. CHUNG, K. HAN, S. K. JANG, and S.-W. LEE
Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus
RNA, August 1, 2004; 10(8): 1277 - 1290.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.